Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
29,248,476
-
Share change
-
+655,232
-
Total reported value
-
$372,959,190
-
Price per share
-
$12.75
-
Number of holders
-
82
-
Value change
-
+$6,499,719
-
Number of buys
-
52
-
Number of sells
-
26
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q4 2017
As of 31 Dec 2017,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
82 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,248,476 shares.
The largest 10 holders included
TRV GP II, LLC, TRV GP III, LLC, FMR LLC, Partner Fund Management, L.P., WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., Redmile Group, LLC, Vanguard Group Inc, Pharmstandard International S.A., and Omega Fund Management, LLC.
This page lists
82
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.